Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06668181 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

StatusRecruiting
PhasePhase 3
Started2025-03-11
View on ClinicalTrials.gov ↗

Amendment history

2026-07-16
Study Status, Contacts/Locations v21
Study sitesdetails revised at 13 of 23 sites
2026-07-02
Study Status, Contacts/Locations v20
Study sitesdetails revised at 3 of 23 sites
2026-06-18
Study Status, Contacts/Locations v19
Study sitesdetails revised at 5 of 23 sites
2026-06-04
Study Status, Contacts/Locations v18
Study sitesdetails revised at 1 of 23 sites
2026-02-26
Study Status, Contacts/Locations v17
Study sitesdetails revised at 1 of 23 sites
Show 16 earlier versions
2026-02-12
Study Status, Contacts/Locations v16
Study sitesdetails revised at 1 of 23 sites
2026-01-28
Study Status, Contacts/Locations v15
Study sitesdetails revised at 1 of 23 sites
2026-01-15
Study Status, Contacts/Locations v14
Study sitesdetails revised at 1 of 23 sites
2025-12-09
Study Status, Eligibility v13
Eligibility criteria+75 characters
[...] JAS] and/or JPsA) defined as having at least 3 active joints, each of which needs to be included in the joints assessed in the JADAS27, and for ERA at least 1 site of enthesitis at Baseline or do [...]
2025-10-09
Study Status, Contacts/Locations v12
Study sites20→23
2025-09-18
Study Status v11
Primary completion date2028-02-22→2028-04-12
Completion date2030-06-24→2030-07-31
2025-06-19
Study Status, Contacts/Locations v10
Study sites16→20
2025-06-05
Study Status, Contacts/Locations v9
Study sites13→16
2025-05-22
Study Status, Contacts/Locations v8
Study sites12→13
2025-05-08
Study Status, Contacts/Locations v7
Study sites10→12
2025-05-05
Study Status, Eligibility v6
Eligibility criteriarevised
[...] Rheumatology (JIA-ILAR) classification criteria of at least 63 months duration prior to the Screening Visit. Study partici [...]
2025-04-10
Study Status, Contacts/Locations v5
Study sites4→10
2025-03-27
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-04→confirmed 2025-03-11
Study sites0→4
2025-03-13
Study Status v3
Start date2025-02→2025-04
2025-02-04
Study Identification, Study Status v2
Start date2024-12→2025-02
2024-11-26
Study Status v1
Start date2024-10→2024-12
2024-10-30
Original filing
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
Trial Details
NCT Number NCT06668181
Lead Sponsor UCB Biopharma SRL
Conditions Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
Enrollment 40 participants
Start Date 2025-03-11
Primary Completion 2028-04-12 (estimated)
Study Completion 2030-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-17